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Editor: G. LinaIn this commentary the authors comment briefly on their own
experiences with the initial introduction of nanopore sequen-
cingdOxford Nanopore Technologies (ONT), Oxford, UKdfor
microbiota-based sequencing [1]. The commentary is based on
joint experiences and collaboration between the Department of
Medical Microbiology & Infectious Diseases and the Unit of Clinical
Bioinformatics at the Erasmus UniversityMedical Center Rotterdam
(Erasmus MC). Initial pilot investigations into the implementation
of nanopore sequencing began around May 2017.
The authors aim to provide feedback and suggestions to com-
panies planning to launch future novel scientific technologies in
this medical field. Furthermore, the authors do not focus on pure
scientific aspects relating to nanopore sequencing (e.g. the original
error rates generated by nanopore sequencing), but rather focus on
more generally applicable topics.
This brief commentary is the authors1' own joint opinion, based
on the use of nanopore for bacterial microbiota profiling, and does
not necessarily reflect the opinions of other users of nanopore
sequencing or of Oxford Nanopore Technologies itself. Finally, the
authors appreciate that many advances have been made in nano-
pore sequencing technology since the technology was first brought
to the market.* Corresponding author. J. P. Hays, Department of Medical Microbiology & In-
fectious Diseases, Erasmus University Medical Centre (Erasmus MC), Rotterdam, the
Netherlands.
E-mail address: j.hays@erasmusmc.nl (J.P. Hays).
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One of the major claims associated with nanopore sequencing
after its commercial introduction in 2015 was that scientists could
perform sequencing in remote locations using a nanopore
sequencing device (‘extreme portability’) Although true, the need
for accessory devices - such as nucleic acid extraction devices and/
or thermocyclers - may not have been fully emphasized in the
marketing campaigns [2]. This is particularly relevant with respect
to two aspects: (a) ancillary devices may not be as portable as the
nanopore technology device itself (or if available may not be widely
used), and (b) the quality of sequencing results obtained (this is
true for all sequencing technologies) is dependent on the quality of
the input DNA/RNA used; extreme portability may mean that de-
vices are used in many different extreme conditions where the
quality of the results obtained may not be easily reproducible or
verifiable. Scientists should look rationally at the claims made by
companies and understand the shortcomings of any new technol-
ogy, including the need for additional ancillary devices and po-
tential quality issues associated with, for example, sample
processing [3].Software upgrades and FAIR (findable - accessible -
interoperable - reusable) data
In the rapidly evolving field of nanopore sequencing, regular
software updates are being introduced by individuals and by ONT
itself. However, the introduction of new software upgrades leads to
problems for researchers (whichever new technology is being
implemented). For example, improvements in bioinformatics
pipelines may be made while a manuscript is in preparation or is
under review, whichmay potentially impact on the final results and
conclusions obtained. Although improvements/upgrades to soft-
ware are always welcome, users of such software should be aware
that their results may be impacted by future software improve-
ments, including comparison with historically published articles.
That said, the adoption and availability of FAIR data will help
facilitate backwards comparison with historical articles, including
nanopore-related research articles, as the historical data could be
rerun using the most up-to-date software available. Anotherublished by Elsevier Ltd. All rights reserved.
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software updates is that FAST5 files, containing raw signal data, are
required in order to perform base call sequencing. FAST5 files are
large (we generated >250 Gb of FAST5 sequence data in a single
Oxford Nanopore GRIDION run), and ~14x larger than base called
FASTQ files- the file format normally saved by users for sequencing
projects. As such, the storage of sequence runs containing large
numbers of FAST5 files (as a safeguard against future software
improvements for base calling) can be a challenge with respect to
the amount of free data storage available and the cost of purchasing
cloud storage or back-up hard drives on which to store the FAST5
data. This impacts on the quality of scientific results in a historical
context, as opposed to impacting on scientific quality in a
geographical context (as mentioned above).
Time to result
The generation of hundreds of thousands of reads and their
subsequent base calling via, for example, Albacore and later Guppy
with Oxford Nanopore Technologies' software may take consid-
erable time (up to 48 h or more) depending on how deep the user
wants the sequence data to be base called. This may be an expe-
rience associated only with microbiota sequencing, but the longer
the user has to wait for results the less rapid nanopore sequencing
becomes. It is therefore perhaps wise for companies with cloud
services to regularly monitor the use of their cloud services so that
they can take steps to proactively adapt capacity to the
(increasing) demand of users as the popularity of their technolo-
gies increases. Further, although very rapid results may be ob-
tained using nanopore sequencing, rapidity may not always be the
driving factor for technology use; think for example about factors
involving sequence coverage coupled to technological convenience
(ease-of-use).
Output data format
Data generated with the easy-to-use bioinformatics software
(see above) provided by ONT will frequently negate the need for
further downstream processing via custom or other forms of
available software. However, from our experience, nanopore-
generated microbiota-based .csv output files require additional
bioinformatics processing i.e., the creation of a specialized script,
before the data can be analysed further. Specifically, the data in
the downloaded .csv file contain TaxonIDs (number codes)
instead of the actual taxonomic names (genus, species etc.) of the
sequenced microorganisms. This means that after our sequencing
experiments, users have to manually, or via specifically designed
command line commands, ‘decode’ the TaxonIDs before further
downstream processing can be performed. This step demands
extra bioinformatics expertise, which reduces the rapidity and
ease-of-use of the nanopore sequencing results. Companies
should, therefore, consider that the format of output data should
be convenient for end users without further need for custom
command line programming, whilst maintaining accuracy by
retaining the TaxonID with the genus and/or the species name.
Website design
Although the continued development of new kits and adap-
tations for novel (including nanopore sequencing) technologies
are welcome, companies should ensure that their websites arePlease cite this article as: Heikema A et al., Lessons learnt from the introd
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use of the kits offered. Scientists need to be able to make intelli-
gent choices about the potential use of new kit variants, with
information presented in an easy-to-read (and searchable) format,
i.e., what, where, when, how. In this respect, the website of ONT
has much improved since its initial appearance. However, in the
past, it was much more difficult to understand the specific
intended application(s) of the various ligation, rapid, barcoding
etc. kits that were available for purchase. Currently more of a
standard practice, but as a reminder, it is useful for companies to
hyperlink publication DOI (digital object identifier) references to
their online kit descriptions so that potential users can identify
the intended use of individual kits. It is also potentially useful to
link kit descriptions to ‘threads’ within social media platforms.
This process could be focused by linking threads to a specific,
platform-based, community of users.The ONT community
Nanopore sequencing is currently ‘for research use only’ and
the potential development and feasibility of clinical diagnostic-
based applications may be in the hands of a growing community
of experienced nanopore sequencing users. Developing
community-based channels on company websites is a good
mechanism for developing new ideas and sharing scientific in-
formation promptly among the users of new technologies. The
question, therefore, is how companies and users can best take
advantage of such communities to facilitate the further develop-
ment of new technologies towards regulatory approved clinical
diagnostic use. For technologies that have a wide range of po-
tential applications, perhaps one helpful solution is to focus their
investment efforts on the ‘critical mass’ accumulated by different
community ‘threads’ (including related scientific publications and
social media presence) in order to help determine the most useful
Target Product Profiles (TPPs e a planning tool that describes the
desired characteristics or ‘profile’ of a product that is aimed at a
particular target disease) [4].Quality standards
One of the difficulties encountered when introducing new
technologies into research and clinical environments is the inclu-
sion of (universally) accepted standard quality control materials
into the new research and diagnostic protocols being developed.
Indeed, the issue of quality in sequencing (and currently especially
microbiota-based sequencing) is a hot topic of concern, with at
least one manufacturer (Zymo Research, USA) [5] currently offering
free microbiota DNA and microorganism standards (January 2020)
as part of a drive to promote universally accepted standardized
microbiological materials for use as external and internal controls.
The use of negative and positive controls per sequence device may
seriously affect throughput and costs when device throughput is
relatively low (e.g. 12 samples per flow cell). Of course, barcoding
and mixing samples may help reduce this problem. However, the
feasibility of this strategy depends on the sequencing depth
required and the amount of time available to complete a
sequencing run. Deciding on minimum quality standards and
controls could be one of the main tasks delegated to a technology's
online community (see also ‘The ONT community’ above).uction of nanopore sequencing?, Clinical Microbiology and Infection,
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